Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.
about
Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatmentMaking the next steps in psoriatic arthritis management: current status and future directionsSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Spondylitic psoriatic arthritis presenting as acute urinary retentionEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasLarge-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.The burden of psoriatic arthritis: a literature review from a global health systems perspective.Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.Biologics in the management of psoriasis.The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisCardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease InitiaIncidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.Cardiovascular risk in psoriatic arthritis - a cross-sectional study.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Etanercept in psoriatic arthritis.Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literatureCumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.Psoriatic arthritis clinical registries and genomics.Psoriatic arthritis: epidemiology, clinical features, course, and outcome.Psoriatic arthritis assessment tools in clinical trials.Predictors for radiological damage in psoriatic arthritis: results from a single centre.Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.Cardiovascular risk in patients with psoriatic arthritis.Guideline for anti-TNF-alpha therapy in psoriatic arthritis.Psoriatic arthritis imaging: a review of scoring methods.Understanding psoriatic arthritis.Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registrySimplified Radiographic Damage Index for Affected Joints in Chronic Gouty Arthritis.Genetic epidemiology of psoriatic arthritis.The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study.Psoriatic arthritis in Asia.Emerging drugs for psoriatic arthritis.
P2860
Q24813979-71E2B53C-1F70-4409-98CA-095271F607A6Q26783506-B2059E4A-42E7-4997-A7AC-CD9D22E6D9E6Q26852081-BE568E73-A937-4FDE-9C1D-791BD0121E64Q30399745-3B283E98-A9F9-442E-878F-651DE2585309Q33628708-6DC79894-B4D9-4475-AE42-0C05537FBD5AQ33659249-425327EA-FF27-49C1-ADD4-2A35E1C402C1Q33858767-46690467-CF29-4AB6-A7EB-C9A6393D467EQ34017619-AE72191C-1182-430F-BA82-FD4E60192DE7Q34027596-F3CFF94C-5684-4086-A1C4-2B482D8093DEQ34432846-50153725-DC30-442A-9341-77A951456B0DQ34562148-B9CA84B9-55CF-4088-8A51-E367112026E5Q34620257-B4199E72-E9EE-4D1B-9C4B-E8F5D9D92408Q34630959-25374462-50C7-40E7-A866-159955C9EED6Q34638027-5EF7405F-3683-4880-9CA6-CFFB0DE470A1Q34668556-7735CE9C-56EC-4DA2-8BBB-F2A8595DCE81Q34700921-1DAAC83E-02E8-47E2-9829-1CD593D26A13Q34717077-A701ABC9-71C2-4E65-8AB9-A73340D2E104Q34986307-4C61C919-FDBB-4BFF-99DA-7B59A40869FDQ35116180-CFE4EF79-F24F-4739-AE05-E4A2B7E9579DQ35168945-7709C050-2488-4716-AC8D-37D49C9A4DA3Q35257745-55B1285E-15A0-4857-8390-725A30AE676DQ35555905-156E4623-FF9C-4FD8-9E74-DF51BD011EA1Q35579414-30AD3F76-FF23-42C2-AD7A-D8C7A5EE1106Q35579437-E244ADA8-8F18-433F-961D-B9E4D736D1CFQ35579462-990818E5-8FC1-4672-9236-CF534FD02E3BQ35760034-9D4E6153-836A-4B28-8655-C8F9C7380756Q35760193-8AC8FA03-D4A6-4EC5-B50E-5E633592770BQ35953347-315A453D-F0CD-44B2-83E4-23BB31C11725Q35974962-07DABA70-3CBA-467C-8E08-63ABED6FC642Q36032569-4687AD62-4F6E-4393-BC87-4DF798777513Q36040076-745D6013-6F4D-43C1-97A0-4BCE8A5C67A9Q36080668-C9A54C72-396C-4336-9B01-7294DD1A3D01Q36472687-3D767DFA-4DBD-4EFD-B8EA-34A93C75BD66Q36656451-804FB1E4-8C1E-424F-BFA6-30B5EDFABA30Q36672842-1AF2248A-BFF4-4471-A477-03F6068CD3C4Q36940942-FFD89AF9-3665-46D0-B633-D67AAF3BE765Q37027264-42DDD1D2-278B-4310-BA37-C2BAD892C5F0Q37280538-7CC463A1-7D9E-48A7-BF4B-1842BD96CF9AQ37588346-D765BE5C-61E4-48A3-A473-E7B8C5021DA7Q37763192-B989C7BB-574A-4640-81D6-057913DD35C6
P2860
Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Mortality studies in psoriatic ...... ognostic indicators for death.
@en
Mortality studies in psoriatic ...... ognostic indicators for death.
@nl
type
label
Mortality studies in psoriatic ...... ognostic indicators for death.
@en
Mortality studies in psoriatic ...... ognostic indicators for death.
@nl
prefLabel
Mortality studies in psoriatic ...... ognostic indicators for death.
@en
Mortality studies in psoriatic ...... ognostic indicators for death.
@nl
P2860
P1476
Mortality studies in psoriatic ...... ognostic indicators for death.
@en
P2860
P304
P356
10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N
P577
1998-06-01T00:00:00Z